ストックスクリーナーアプリを入手
0.6093
2.75%
0.0163
アフターアワーズ：
.60
-0.0093
-1.53%
Moleculin Biotech Inc (MBRX) 最新ニュース
Moleculin (MBRX) Daily Snapshot: Climbs 0.49% to $0.61 for the Current Session; the Price Remains Bounded by the Supplied Support and Resistance at the CloseMcClellan Oscillator - vinanet.vn
Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Cuts Target Price to $2 - Moomoo
Moleculin Biotech Releases Q2 2026 Financial Results - AlphaStreet
Moleculin Biotech (NASDAQ: MBRX) seeks reverse split and plan changes at 2026 meeting - Stock Titan
Why Did MBRX Stock Climb 14% Today? - Stocktwits
Moleculin Biotech 2Q Research and Development Expenses $5.5M >MBRX - Moomoo
Moleculin Biotech expects cash position to fund operations into Q1 2027 - TradingView
Form 8K Moleculin Biotech Inc For: 14 August By Investing.com - Investing.com Canada
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial - The Manila Times
Moleculin Biotech reports Q2 2026 loss of $7.6M, cash $7.3M; MIRACLE trial interim efficacy positive - TradingView
Moleculin Biotech Reports Second Quarter 2026 Financial - GlobeNewswire
Moleculin Biotech Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Moleculin Biotech (NASDAQ: MBRX) advances AML trial but warns on cash - Stock Titan
Moleculin Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
MBRX Q1 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage InvestmentLow Growth Earnings - vinanet.vn
Moleculin Biotech (MBRX): CVI and Heights disclose 1.86M-share, 9.9% ownership - Stock Titan
Q1 2025 Moleculin Biotech Inc Earnings Call Transcript - GuruFocus
Moleculin Biotech, Inc. Actuals & Estimates (NASDAQ:MBRX) - TradingView
Moleculin Biotech Inc expected to post a loss of $1.54 a shareEarnings Preview - TradingView
Moleculin Biotech (MBRX) stake capped at 4.99% under Intracoastal warrants - stocktitan.net
Moleculin Biotech, Inc. (MBRX) CFO buys 293,333 shares and 879,999 warrants - Stock Titan
Moleculin Biotech, Inc. (MBRX) CEO adds stock and 1.6M Series I warrants - Stock Titan
Moleculin Biotech (MBRX) CSO buys common stock and Series I Warrants - stocktitan.net
Price to sales forward of Moleculin Biotech, Inc. – LS:A41SET - TradingView
Moleculin reports promising preliminary phase II/III data for leukaemia drug Annamycin - Indian Pharma Post
Moleculin Biotech Raises $9.3 Million Equity; Signs Placement, Purchase and Lock-Up Agreements - TradingView
Form 424B5 Moleculin Biotech Inc For: 3 August By Investing.com - Investing.com South Africa
Moleculin Biotech Reports Positive Pivotal Phase 2/3 Trial Results for Annamycin in AML - The Indian Practitioner
Weekly Recap: MIRACLE Part A response rates and $0.75 unit offering - TradingView
Moleculin Biotech, Inc. SEC Filing (Aug 3, 2026) - Stock Titan
Moleculin Biotech (NASDAQ: MBRX) prices $9.3M stock and warrant offering - Stock Titan
Moleculin Biotech prices $9.3 million public offering By Investing.com - Investing.com Canada
Moleculin Announces Pricing of $9.3 Million Public Offering - marketscreener.com
Moleculin reports blinded remission data from leukemia trial By Investing.com - Investing.com Canada
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients - The Manila Times
Moleculin Biotech (MBRX) Registration filing Summary - Quartr
IPO Databook: Moleculin Biotech (MBRX US)Jul 2026 - Smartkarma
Form S-1 Moleculin Biotech Inc For: 29 July By Investing.com - Investing.com Nigeria
Moleculin Biotech Files Registration Statement for Public Offering; Shares Fall - Moomoo
MBRX|Moleculin Biotech Inc|Price:2.190|Chg%:+0.070 - TradingKey
Moleculin Biotech Inc (MBRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Moleculin Biotech, Inc. Revenue Breakdown – NASDAQ:MBRX - TradingView
TradingKey - TradingKey
Enterprise value to EBIT forward of Moleculin Biotech, Inc. – NASDAQ:MBRX - TradingView
MBRX|Moleculin Biotech Inc|Price:2.160|Chg%:-0.030 - TradingKey
Moleculin Biotech Inc (MBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Moleculin Biotech Inc (MBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Moleculin Biotech Inc (MBRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Moleculin Biotech Inc (MBRX) Institutional Confidence - TradingKey
MBRX|Moleculin Biotech Inc|Price:2.150|Chg%:+0.030 - TradingKey
MBRX|Moleculin Biotech Inc|Price:2.160|Chg%:+0.040 - TradingKey
Moleculin Biotech Inc (MBRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Moleculin Biotech Inc (MBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Moleculin Biotech Inc (MBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MBRX stock trades around recent lows as Moleculin focuses on cash runway and clinical progress - Ad-hoc-news.de
Moleculin Biotech (MBRX) Declines 2.38% as Stock Tests Key Support at $1.95Corrective Wave - vinanet.vn
MBRX stock holds the line as Moleculin advances its pipeline - Ad-hoc-news.de
MBRX Q1 2026 Earnings: Wider-Than-Expected Loss Reflects Continued R&D InvestmentHealthcare Earnings Report - dars.gov.et
Enterprise value to revenue forward of Moleculin Biotech, Inc. – GETTEX:MOL0 - TradingView
Price to sales forward of Moleculin Biotech, Inc. – GETTEX:MOL0 - TradingView
Price to book forward of Moleculin Biotech, Inc. – GETTEX:MOL0 - TradingView
Moleculin Biotech (MBRX) Weakens: Stock Drops 6.56% as Key Support Levels TestedTrend Reversal Picks - dars.gov.et
0.00%
3.22%
大文字化:
|
ボリューム (24 時間):